Advocating for a world where intellectual
property law serves the public interest.

A TREATY ON COPYRIGHT EXCEPTIONS AND LIMITATIONS FOR EDUCATIONAL AND RESEARCH ACTIVITIES (TERA)

39 education and research organizations, including the 30 million members of Education International, are calling upon the World Intellectual Property Organization to adopt a Treaty on Copyright Exceptions and Limitations for Educational and Research Activities (TERA). TERA is open for endorsement by organizations and individuals. The Treaty was adopted at the Global Congress on Intellectual Property and the Public Interest

Sanef Celebrates the Inclusion of the “Fair Use” Principle in the Copyright Amendment Bill

[South African National Editors Forum] SANEF celebrates the unanimous decision taken yesterday by the Parliamentary Portfolio Committee on Trade and Industry to include the principle of “fair use” in the Copyright Amendment Bill. The principle of “fair use” allows for the use of copyrighted material for a limited or “transformative” purpose such as to quote the latter or use pictures

Ciencia Abierta y Conocimiento Libre Para un Futuro Incluyente y Justo

[Alex Argüelles] Especialistas y activistas de la cultura libre en América Latina y El Caribe están buscando nuevas maneras de incidir en las políticas públicas ligadas al acceso a la cultura en todas sus variantes. A través de una declaración producida colectivamente, buscan establecer un referente para el avance de la región en torno a la ciencia abierta.

Democratising Knowledge: A Report on the Scholarly Publisher, Elsevier

[Jonathan Tennant] Executive Summary: Elsevier are the largest and most powerful scholarly publisher, a status achieved through a long history of mergers and acquisitions and rigorously capitalistic business practices. The core issues surrounding Elsevier are that it operates its business primarily through charging for what should be public knowledge and education, with aggressive pricing strategies and marketing tactics that are

MPP-AbbVie License on Glecaprevir and Pibrentasvir (G/P): Backtracking on Geographic Coverage but with Options for Oppositions, Compulsory Licenses, and Negotiated Territorial Expansion

AbbVie and the Medicines Patent Pool have negotiated a royalty-free licensing and sublicensing agreement on a priority hepatitis C direct acting antiviral, glecaprevir and pibrentasvir (G/P). This G/P combo is recommended by the WHO as a pan-genotypic adult first-line regimen with ongoing Phase 3 trials for adolescents and children. G/P has a high resistance barrier and the shortest treatment duration

Defining the Relevant Market in Fair Use Determinations

[Xiyin Tang] Abstract: The fair use defense is frequently invoked as the most important First Amendment safeguard in copyright law, and the effect a defendant’s use has upon the potential market for the copyrighted work is often cited as the most important factor in that determination. Yet courts and commentators alike have struggled with how to define the potential market